Collaboration Expected to Advance FS2 Topical Platform and Strengthen BGLC’s Biotech Footprint in AsiaKUALA LUMPUR, Malaysia, Oct. 20, 2025 (GLOBE NEWSWIRE) -- BioNexus Gene Lab Corp (Nasdaq: BGLC, “BGLC”, or the “Company”), today announced that it has entered into a non-binding Strategic Partnership Term Sheet with BirchBioMed Inc. (“Birch”), a Canadian biopharmaceutical company developing regenerative treatments for organ fibrosis, topical scarring and autoimmune diseases. Under the non-binding term sheet ...